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The role of PKC-θ in CD4+ T cells and
HIV infection: to the nucleus
and back again
Chansavath Phetsouphanh* and Anthony D. Kelleher
The Kirby Institute of Infectious Diseases in Society, University of New South Wales, Sydney, NSW, Australia
Protein kinase C (PKC)-θ is the only member of the PKC family that has the ability to
translocate to the immunological synapse between T cells and antigen-presenting cells
upon T cell receptor and MHC-II recognition. PKC-θ interacts functionally and physically
with other downstream effector molecules to mediate T cell activation, differentiation,
and migration. It plays a critical role in the generation of Th2 and Th17 responses and
is less important in Th1 and CTL responses. PKC-θ has been recently shown to play a
role in the nucleus, where it mediates inducible gene expression in the development of
memory CD4+ T cells. This novel PKC (nPKC) can up-regulate HIV-1 transcription and
PKC-θ activators such as Prostratin have been used in early HIV-1 reservoir eradication
studies. The exact manner of the activation of virus by these compounds and the
role of PKC-θ, particularly its nuclear form and its association with NF-κB in both the
cytoplasmic and nuclear compartments, needs further precise elucidation especially given
the very important role of NF-κB in regulating transcription from the integrated retrovirus.
Continued studies of this nPKC isoform will give further insight into the complexity of T cell
signaling kinases.
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Introduction
CD4+ T cells play a central role in the function of the immune system; they help B cells to produce
antibodies, they can also orchestrate CD8+ T cells and macrophages against a wide variety of
pathogens, and CD4+ T cells can also become cytotoxic cells that are capable of direct cell killing
(1–4). However, these functional roles depend on the ability of the T cell receptor (TCR) to recognize
its cognate antigen (5, 6).
T cell activation initiates when the TCR and associated CD3 proteins recognize a peptide/major
histo-compatibility complex (MHC) on antigen-presenting cells (APCs) causing rapid clustering of
TCR-associated molecules and associated co-receptors to form the immunological synapse (IS) (7).
The T-cell component of the synapse is focused on clustering of CD3 (α, γ, δ, and ζ) and TCR
(α, β), which bind specifically to the peptide/MHC complex, as well as CD4, which stabilize this
interaction by binding to non-polymorphic regions of MHC class II (7, 8). This interaction triggers
the TCR signaling process.
Recognition of cognate antigenic peptides on MHC molecules triggers TCR signaling, but it is
co-stimulatory and co-inhibitory molecules (collectively co-signaling molecules) that direct T cell
function and determine cell fate (9). The discovery of CD28 as a TCR co-stimulator provided
evidence of the two-signal model of T cell activation, where TCR and co-stimulatory signaling
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is required for full T cell activation (10). Co-signaling receptors are
now broadly defined as cell-surface molecules that have the abil-
ity to transduce signals, positively (co-stimulatory receptors) or
negatively (co-inhibitory receptors) from the IS into T cells (11).
Studies from the past few decades on TCR signaling pathways
have revealed and characterized many types of effector/signaling
molecules that are pivotal to T cell activation pathways (12).
Early studies revealed that TCR engagement led to phospholi-
pase C-γ1 (PLC γ1)-mediated hydrolysis of membrane inositol
phospholipids that resulted in the subsequent production of inos-
itol phosphate and diacylglycerol (DAG). These lipid esters were
found to increase intracellular calcium (Ca2+) concentrations and
activate certain protein kinase C (PKC) isoforms (13). Further-
more, Ca2+ and phorbol ester tumor promoters [e.g., phorbol
myristate acetate (PMA)] were able to mimic the TCR and co-
receptor signals that lead to full T cell activation, resulting in IL-2
production and proliferation (14, 15), which are important for
the elicitation of rapid T cell responses in vitro. Interestingly, this
mode of activation essentially bypasses the cell surface ligands
required for normal T cell activation.
The discovery of PKC as a lipid and Ca2+-dependent ser-
ine/threonine kinase that acts as a cellular receptor for tumor-
promoting phorbol esters demonstrated the important role of PKC
in T cell activation (16). The importance of PKC in T cell acti-
vation was substantiated by experiments that showed depletion
of cellular PKC by prolonged phorbol ester treatment and PKC
inhibition via pharmacological drugs, resulted in blockage of T
cell activation (17). While the role of PKC isoforms in signaling
cascades in the cytoplasm have been increasingly well described
in a range of cell types, more recently it has been recognized that
PKC-theta (θ) can also localize to the nucleus where it appears to
play a distinct role. This review will focus on the importance of
protein complexes that involve kinases (PKCs) in CD4+ T cells;
particular emphasis will be placed on the role of PKC-θ in the IS
and its newly discovered role within the nucleus.
The Protein Kinase C Family
Protein kinase C was discovered in 1977 by Yasutomi Nishizuka
and his group, when they purified a cyclic nucleotide-
independent, Ca2+- and lipid-dependent, kinase from rat
and bovine cerebellum (18, 19). The PKC family consists of 12
related isoforms which can be divided into three groups based on
isoform structure and their corresponding co-factors/activators,
these include: conventional (cPKCs), novel (nPKCs), and atypical
(aPKCs) (20, 21). Isoforms α, β, and γ are cPKCs, which are
activated by DAG, phorbol ester (PMA), and Ca2+, in the
presence of phosphatidyserine (18, 19). nPKC consist of ε, η,
δ, and θ isoforms, all of which are only activated by DAG and
phorbol esters (e.g., PMA). The aPKC group isoforms are not
activated by Ca2+, DAG, or PMA, but depend on protein–protein
interactions for activation. Members of this group include
isoforms ι, ζ, and µ (21, 22). An additional group, and sometimes
considered as a fourth group of PKCs are the PKC-related kinases
(PRKs). This group consists of three members: PRKs1–3 (23).
The structure of these PRKs differs slightly from PKCs and they
bind to ras-homology member A (RhoA) for activation (24, 25).
The Novel PKC Member: PKC-θ
Protein kinase C-θ was first isolated and characterized in the early
1990s by Altman et al. (26), as they were searching for nPKC
isoforms that may have a distinct role in T cell development
and/or activation (12). Other investigators later cloned PKC-θ
cDNA from both humans and mice from various tissues (27, 28).
Chromosomal mapping identified the location of human PKC-θ
gene (PRKCQ) within the short arm of chromosome 10 (10p15),
which is a locus that has been previously recognized as being
associated withmutations that lead to T cell lymphomas and other
T cell immunodeficiencies (29, 30).
Protein kinase C-θ shares its regulatory N-terminal domain
andC-terminal catalytic domainwith other PKC familymembers,
and is most highly related to nPKC-δ as the V1 domain of the two
enzymes shares 49%homology (26). PKC-θ is primarily expressed
in lymphoid tissues, hematopoietic cells, and muscle cells (31–
33). Murine studies have revealed that there is relatively restricted
pattern of expression in these compartments. Subsequent analyses
using different lymphoid and myeloid cell types demonstrated
that there is selective expression of PKC-θ in T cells and not
B cells, neutrophils, monocytes, or macrophages. Furthermore,
PKC-θ expression was found in platelets and not erythrocytes
(34). Within T cells, single-positive CD4+ and CD8+ periph-
eral blood T cells and CD4+ CD8+ double-positive thymocytes
express high levels of PKC-θ protein (35).
Protein kinase C-θ is the only member of the PKC family that
has the ability to translocate to the IS between T cells and APCs
upon TCR and MHC-II recognition. PKC-θ can also be activated
as a result of G-protein-coupled receptor and hormone receptor
signaling (36). The maturation of PKC-θ involves a sequence of
phosphorylation steps, which involves PDK1 (phosphoinositide-
dependent kinase 1) phosphorylating the activation-loop site of
PKC-θ (37, 38). After PDK1 phosphorylation, the “hydropho-
bic” and “turn” motifs in the C-terminal domain of PKC-θ are
exposed and further autophoshporylation stabilizes the enzyme.
The “mature” PKC-θ is now primed for activation and is released
into the cytosol, where it is in an inactive conformation (39). Upon
receptor stimulation PKC-θ translocates to the plasmamembrane,
due to intracellular increases in DAG. DAG binding to the C1
domain confers high-affinity interaction between PKC-θ and the
membrane (40). This leads to conformational change that allows
the release of the pseudo-substrate domain from the substrate-
binding site. PKC-θ is now in an “active” state and is accessible for
substrate binding, phosphorylation, and activation of downstream
effector molecules (36, 41). PKC-θ interacts functionally and
physically with other downstream effector molecules to mediate
T cell activation, differentiation, and migration (23, 42, 43).
The Role of PKC-θ in the T Cell Synapse
Immunological synapses form between a T cell and an antigen-
presenting cell, following peptide recognition via the TCR and
MHCmolecules. The synapse acts as the interface between the two
cells and is formed by specific protein aggregation. The synapse
is composed of two regions: the central core supramolecular
activation cluster (cSMAC) that is surrounded by a peripheral
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supramolecular cluster (pSMAC) (44). Lipid rafts do not increase
in the IS, but rather the rafts are reorganized preferentially in the
cSMAC upon TCR/CD28 stimulation (45). The cSMAC encom-
passes the TCR and co-stimulatory receptor tails, whereas the
pSMAC contains adhesion molecules (e.g., LFA-1) (44). PKC-θ
is the only member of the PKC family that is recruited to the c-
SMAC of the IS (43). PKC-θ is recruited to the cSMAC/pSMAC
junction and is dependent on physical association with the cyto-
plasmic tail of CD28 (46, 47). More specifically, PKC-θ is located
in the TCRlow “ring” of the cSMAC where it co-localizes with
CD28 for signaling initiation. The TCRhigh compartment of the
cSMAC is where signal termination and internalized signal com-
plex degradation occur (48, 49).
Protein kinase C-θ translocation to the cSMAC is mediated
by its regulatory V3 domain (proximal to the catalytic domain)
and requires Lck (lymphocyte-specific protein tyrosine kinase). In
stimulated T cells, Lck is recruited to the tyrosine-phosphorylated
P190Y*AP (PRmotif) found in the cytoplasmic tail of CD28, via its
SH2 domain. The interaction between the PXXP motif of PKC-
θ V3 and the SH3 domain of Lck is necessary for PKC-θ and
CD28 co-localization (50, 51). The CD28–Lck–PKC-θ interac-
tion is thought to be responsible for the reorganization of lipid
rafts, auto-phosphorylation and activation of Lck, stabilization of
IL-2 mRNA expression, and other additional biological functions
(47, 49, 52).
PKC-θ is Critical for T Cell Activation and
IL-2 Production
T cell receptor engagement and CD28 interaction initiates a series
of PKC-θ-dependent events that eventuate in activation of tran-
scription factors, such as NF-κB, AP-1, and NFAT, which are
critical for CD4+ T cell activation, proliferation, and differenti-
ation (53–55). NF-κB (nuclear factor kappa b) is a major target of
activatedPKC-θ and this interaction leads to IL-2 production.NF-
κB is generally in an inactive formwithin the cytoplasm, where its
nuclear localization signal (NLS) is masked by the multi-subunit
inhibitor κB (IκB). These inhibitors undergo degradation when
IκB kinases (IKK) become activated via PKC-θ phosphorylation,
leading to nuclear translocation of NF-κB (56, 57). However, this
process requires other effector molecules that link via PKC-θ to
NF-κB IKK complex. Phosphorylation of caspase activation and
recruitment domain (CARD) and membrane-associated guany-
late kinase (MAGUK) domain-containing protein-1 (CARMA1)
by activated PKC-θ (58–60) promotes CARMA1 to associate
with Bcl10 (B-lymphocyte lymphoma/leukemia 10) and mucosa-
associated lymphoid tissue 1 (MALT1) proteins, which leads to
activation of the IKK complex (58, 59).
Other transcription factors regulated by PKC-θ are AP-1 and
NFAT. AP-1 (activator protein-1) is a dimer of Jun (c-Jun, JunB,
and JunD) and/or Fos (c-Fos, FosB, Fra-1, Fra-2, and FosB2)
family proteins. De novo synthesis, phosphorylation, and dephos-
phorylation of Jun and Fos proteins regulate AP-1 activity. There
are two AP-1 binding sites located in the IL-2 enhancer region
[ 150 bp (proximal) and  180 bp (distal)] (61, 62). It was dis-
covered that PKC-θ was the only PKC isoform that can regu-
late AP-1 enhancer activation in a Ras-dependent manner (53).
NFAT (nuclear factor of activated T cells) is another transcription
factor that is regulated by PKC-θ. The transactivation and nuclear
translocation of NFATp and NFATc is impaired in PKC-θ-
deficient mice (63). Later experiments showed that upon TCR
stimulation, NFAT is dephosphorylated by calcineurin, which
forms a functional partnership with PKC-θ. The association of
Ca2+/calcineurin and PKC-θ leads to the activation and nuclear
translocation of NFAT that eventuates into IL-2 production in
activated T cells (64).
Multiple Functions of PKC-θ in CD4+ T Cell
Subsets
In vitro and in vivo studies using PKC-θ-deficient (Prkc1 / )
mice demonstrated that PKC-θ has differential functions in dis-
tinct T cell subsets (47, 65). PKC-θ was found to be pivotal for
Th2-type immune responses to allergens and helminth infections.
However, PKC-θ was dispensable for Th1-dependent resistance
to Leishmania major and for CTL-mediated antiviral responses.
PKC-θ was essential for the induction of Th17-mediated EAE
(experimental autoimmune encephalitis), a model of multiple
sclerosis (66, 67). In vitro proliferation studies demonstrated that
PKC-θ was crucial for Th2 and Th17 development, but only mod-
erately affected Th1 differentiation, as PKC-θ-deficient T cells
were still able to differentiate into Th1 cells (65, 68, 69). Overall,
PKC-θ plays a stronger role in the generation of Th2 and Th17
responses and is less important in Th1 and CTL responses. These
observations showed the importance of PKC-θ in the regulation
of the adaptive immune response in particular effector T cells,
prompted the question regarding its role in regulatory T cells
(Treg).
In contrast to effector T cells, PKC-θ was found to mediate
negative feedback on Treg suppressive function. Activation of
Tregs caused the sequestration of PKC-θ away from the cSMAC,
and repression of PKC-θ via inhibitors increased the suppressive
activity of Tregs (70). However, in vivo studies showed that PKC-
θ was necessary for natural Treg development in the thymus,
as PKC-θ knockout mice showed impaired Treg numbers in the
periphery, although the function of the activated mature Treg
in the periphery remained unaltered (43, 47, 70, 71). It appears
that PKC-θ plays a negative role in Treg function; sequestration
of PKC-θ improves their suppressive activity in the presence of
inflammatory cytokines. Higher levels of PKC-θ were observed
in Tregs compared to T effectors, however, even with CD28 co-
stimulation, PKC-θ appears to be sequestered away from the IS
in Tregs. There was also reduced CARMA1 recruitment in asso-
ciation with PKC-θ sequestration (70, 72). However, a possible
reason for improved suppressive activity of Tregs is that inhibition
of PKC-θ prevents Tregs fromTNF-α-mediated inactivation (73).
It was also observed that PKC-θ inhibition enhanced survival
of mice from inflammatory colitis and restored Treg activity in
rheumatoid arthritis patients (70).
PKC-θ and T Cell Anergy
Protein kinase C-θ has also been implicated in playing a role in T
cell anergy. T cell anergy is a major mechanism that maintains
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peripheral T cell tolerance. T cell anergy is induced by TCR
engagement with inappropriate co-stimulatory signaling, render-
ing the T cell into an unresponsive state (74). T cell anergy is
also associated with deficient IL-2 production, as the CD28/B7
signaling pathway is defective (75). As PKC-θ acts as an important
effector molecule downstream of CD28 signaling, any defects
in co-stimulation may inhibit PKC-θ effector functions. PKC-θ-
deficient T cells are not able to up-regulate anti-apoptotic factors
such as Bcl-2 and Bcl-xl and undergo accelerated apoptosis (76,
77). PKC-θ has been shown to phosphorylate the pro-apoptotic
molecule BAD (Bcl-2-associated death promoter), inactivating it
and thus promoting T cell survival (78). The pro-oncoprotein,
c-Cbl, is another molecule that has been shown to negatively
regulate T cell function. c-Cbl can associate with the adapter
protein LAT (linker for activation of T cells) and can act as a
negative regulator of PTKs (protein tyrosine kinases) Fyn, Syk,
and Zap70 and thus cause T cell anergy (79). PKC-θ-mediated
phosphorylation of serine and tyrosine residues of c-Cbl prevents
its inhibitory effect. Phosphorylation of c-Cbl by PKC-θ inhibits
the recruitment of Sh2-containing proteins and subsequent asso-
ciation of cbl E3 ubiquitin ligase with its target proteins (80).
PKC-θ in the Nucleus
Recently Sutcliffe et al. have demonstrated a new role for PKC-θ
within the nucleus. PKC-θ was found to contain a NLS domain
and in silico analyses have revealed that AKT1, HABP4, CHD3,
andTCLA1 are candidate proteins thatmay facilitate the transport
of PKC-θ into the nucleus (81). PKC-θ was associated with medi-
ating inducible gene expression in the development of memory
CD4+ T cells (82). It was found that chromatin-tethered PKC-θ
forms an active nuclear complex by interacting with other nuclear
proteins, including RNA polymerase II, the histone kinase MSK-
1, the demethylase LSD-1, and the adaptor molecule 14-3-3ζ at
regulatory regions of inducible genes, including IL-2 (Figure 1).
Moreover, genome-wide analysis identified numerous nPKC-θ
FIGURE 1 | The role of PKC-θ in T cell activation. PKC-θ becomes activated in the immunological synapse that starts a signaling cascade, which leads to
translocation of NF-κB into the nucleus for IL-2 expression and T activation. PKC-θ can also traverse the nuclear membrane and causes transcription of inducible
genes via its binding partners.
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target genes and microRNAs that are implicated in T cell devel-
opment, proliferation, differentiation, and apoptosis (81–83).
The ability of PKC-θ to induce transcription was confirmed in
mesenchymal transition and breast cancer stem cells, where PKC-
θ was able to elicit inducible transcription programs that drive
mesenchymal differentiation and cancer stem cell formation (84).
However, the exact role of PKC-θ in the nucleus whether it retains
its kinase activity and the existence of other potential binding
partners remains to be investigated.
PKC-θ in HIV Infection
HIV-1 negative element Nef gene plays a key role in disease
progression. Nef has been associated with PKCs that phospho-
rylate Lck and the N-terminus of Nef (85). PKC-θ has been
implicated as a possible physiological cofactor of Nef, and can pro-
mote NFAT-dependent gene expression and subsequently T cell
activation (86). Recently, investigations using specific inhibitors
demonstrated that PKC-θ has the ability to increase replication
of latent HIV-1 through modulation of transcription from the
integrated genome. HIV-1 also induced higher PKC-θ phospho-
rylation levels in infected CD4+ T cells. Inhibition of PKC-θ also
hindered its translocation to the plasma membrane, which leads
to a reduction in HIV-1 retro-transcription via partial repression
of SAMHD1 (SAM domain and HD domain-contain protein1).
Inhibitor treatment did not completely abolish T cell function
as the CD4+ T cells were still able to proliferate and IFN-γ
production by CD8+ T cells remained unaffected, thus avoiding
total immunosuppression (87).
Phorbol myristate acetate, as well as the non-tumor-promoting
deoxyphorbol ester Prostratin, an activator of PKC, and related
compounds such as byrostatin and other engineered synthetic
derivatives (88, 89) have been used in vitro to activate latently
infected cells for HIV-1 eradication. These esters were shown
to stimulate rapid nuclear translocation of NF-κB and activa-
tion of HIV-1 long terminal repeat (LTR) in a κB enhancer-
dependent manner, via PKC. These compounds have been
assessed with regard to their binding affinity to PKC-δ, rather
than PKC-θ (89, 90). Therefore, the exact manner of the acti-
vation of virus by these compounds and the role of PKC-
θ, particularly its nuclear form and its association with NF-
κB in both the cytoplasmic and nuclear compartments, need
further precise elucidation especially given the very important
role of NF-κB in regulating transcription from the integrated
retrovirus.
In addition, the issue of systemic activation of non-infected
cells by these compounds may be advantageous or problematic.
While ideally the specific cell type harboring HIV-1 should be
targeted to allow specific activation of only infected cells, there
may be potential advantages of more generalized T cell activation
by these compounds (91, 92). As explained previously, PKC-θ
appears to play a complex role in the regulation T cell subsets
including the balance between Th1 and Th2 cells and in the num-
ber and function of CTL and Treg. Depending on the net effects
of specific PKC-θ activators, their effects may help or hinder the
clearance of cells carrying reactivated virus (93). While in vitro
experiments may give some insight to outcomes, it is likely that
in vivo experiments in models, such as humanized mice, will be
required to dissect these effects. These findings demonstrate that
PKC-θmay play an important role in HIV-1 pathogenesis, and its
role in the nucleus in the context modulating HIV transcription
requires further investigation.
Conclusion
Protein kinase C-θ is a serine/threonine-specific kinase that has
been extensively studied as a core component of the IS, and has
been shown to play a central role in T cell activation downstream
of TCR and co-stimulatory molecule engagement (76, 94). Other
interesting facets of PKC-θ are its recently described function in
the nucleus. The relative roles of these two facets of PKC-θ and
the precise mechanism of action of this molecule in the nucleus
are still being dissected. The relatively restricted distribution of
PKC-θ is a potential advantage as a target for pharmacological
intervention. Drugs that target PKC-θ have a potential role in
modulating not only T cell function but also in the interaction
of these cells with viral pathogens, particularly lymphotrophic
viruses such as HIV. In addition, given the complex interactions
involved in the processes regulating host and HIV transcription,
targets such as PKC-θ, particularly after its translocation to the
nucleus may have advantages in the manipulation of the latent
integrated provirus and provide more potent and specific tools
in the quest for viral eradication than the other classes of drugs
currently being explored for this purpose.
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